跳至主要内容
临床试验/NCT01345084
NCT01345084撤回3 期

A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, with or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck

Eurofarma Laboratorios S.A.8 个研究点 分布在 1 个国家开始时间: 2013年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
撤回
发起方
试验地点
8
主要终点
Overall survival

研究概览

简要总结

Primary: to compare the overall survival defined as the time elapsed between the randomization date and death due to any cause, in both treatment groups.

Secondary: to compare the progression-free survival, incidence of locoregional failure, site of the first recurrence/progression, objective response rate assessment, quality of life assessment and incidence of adverse events.

详细描述

This is a phase III, superiority, national, open-label, randomized, and two-arm study.

Patients' enrollment will be performed only after approval by competent regulatory authorities and it will last up to 12 months.

All patients taking part in the study must sign an informed consent. The patients will have stage III or IV, unresectable head and neck SCC, performance status 0 or 1.

Randomization and treatment assignment will be performed by a company specifically contracted for such purpose and will be per research site and disease stage, 1:1

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Radiation therapy, cisplatin and nimotuzumab

Experimental

Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months.

Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week

Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses)

干预措施: Nimotuzumab (Drug)

Radiation therapy and cisplatin

Active Comparator

Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week

Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)

干预措施: Radiation Therapy (Radiation)

Radiation therapy and cisplatin

Active Comparator

Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week

Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)

干预措施: Cisplatin (Drug)

结局指标

主要结局

Overall survival

时间窗: 6 months

Local control of disease will be measured by magnetic resonance imaging (MRI) and physical examination 6 weeks after treatment end.

次要结局

  • Complete clinical response rate(2 years)

研究者

发起方
Eurofarma Laboratorios S.A.
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验

Study Comparing Radiation Therapy and Chemotherapy... | 临床试验